

Oral Reticular Lichen Planus: Diagnosis & Management.

Dr. Shubham Katakwar¹, Dr. Basavaraj T. Bhagawati.², Dr. Pritam Pohankar³,
Dr. Shilpa Panzade⁴, Dr. Prerana Waghmare⁵, Dr. Anjali Ghate⁶.
PG student ^{1, 4, 5, 6}, Prof. & HOD², Senior Lecture³

Department of Oral Medicine and Radiology, Saraswati Dhanwantari Dental College & Hospital & Post-Graduate Research Institute, Parbhani, Maharashtra, India.

Abstract

Lichen planus is a chronic systemic disease that commonly involves mucosa and skin. Thus the objective of paper is to report a case of lichen planus in male patient and discuss the main aspects of this disease in relation to etiopathogenesis and treatment.

Keyword -Oral lichen planus (OLP), Systemic corticosteroids

Introduction

Lichen in greek means tree moss and planus means flat. Lichen planus was first reported by Erasmus Wilson in 1869.¹ Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous disorder, affects skin and mucosa and its stratified squamous epithelia, with a prevalence of 0.02% - 1.2% more commonly seen in females.² This disease is most often reported in middle-aged patients 30-60 years of age with a female to male ratio 1.4:1. Rarely, OLP is seen in children.³ It is believed that the disease is caused by an abnormal cell mediated immune response of both T4 and T8 lymphocytes in the basal epithelial cells. Autocytotoxic CD⁸⁺ T-cells activate apoptosis of oral epithelial cells. The CD⁸⁺ cytotoxic cells trigger the keratinocyte apoptosis through activation of the cells by an antigen associated with major

histocompatibility Class I on basal keratinocytes. The chronic course of OLP may result from the activation of the inflammatory mediator nuclear factor kappa B, and the transforming growth factor control pathway may cause keratinocyte hyper proliferation that leads to the white lesion.⁴

OLP (also termed oral mucosal lichen planus), is a form of mucosal lichen planus, where lichen planus involves the oral mucosa, the lining of the mouth. Six clinical forms of oral lichen planus are recognized which are a) Reticular b) Plaque c) Papular d) Bullous e) Erosive / Ulcerative.⁵⁻⁶

Here we report a case on reticular lichen planus, which involve both sides of buccal mucosa in its clinical presentation and its effective treatment using synthetic corticosteroids and topical corticosteroids.

Case report

A 52 year old medically fit male patient reported to our department with a chief complaint of burning sensation while having food, since duration of approximately one year. The patient gave history of episodes of intermittent burning sensation on both sides of cheek, which mainly aggravated on having food, which relieved on its own. Patient's medical and family histories were non-contributory. Patient had smoking habit since last 25 years. The patient had visited many dentists before for the same chief complaint and dentist prescribed local anesthetic ointment for relieving burning sensation.

On clinical examination, interlacing white keratotic striae with erythematous borders giving a web-like appearance were seen on right buccal mucosa and left buccal mucosa and vestibular region [Figure 2 to 3]. On palpation the lesion was non-scrapable. Other clinical findings included missing teeth in relation to maxillary right first pre molar to left maxillary first molar. Based on the clinical presentation a provisional diagnosis of reticular lichen planus of right and left buccal mucosa was given. The patient was advised for incisional biopsy. But as the patient was not willing for biopsy then, he was advised a regimen of anti-oxidants (Cap.A Charge®), Systemic

corticosteroids (Tab.Wysolone 10mg® contains prednisolone 10mg) once a day and Topical corticosteroids (Kenacort 0.1% ® contains Triamcinolone 0.1%). Patient was asked to report for periodic recall after every two weeks. The lesion regressed almost within 2 weeks and chief complaint of burning sensation resolved completely [Figure 4]. Then, we shifted the dose of Tab Wysolone 10mg to 5mg once a day. The prognosis was excellent and after a period of just one and half months the lesion had regressed completely and the patient's oral mucosa was back to normal [Figure 5]. Patient was further recalled after one, three and six months; no incidence of recurrence was seen.

Discussion

Lichen planus is a mucocutaneous disease characterized by a cellular inflammatory infiltrate enriched by CD4+ cells. These cells with the presence of acidophilic bodies causes the apoptosis and vacuolation of epithelial cells, causing degeneration of the basal epithelial layer of affected mucosa.⁷ Globally, OLP affects about 1-2% of population and prevalence in India ranges from 0.1-1.5%. OLP can develop on any mucosal surface including larynx and oesophagus but lesions are most commonly noted on the posterior buccal mucosa which is similar to present case. The specific

etiology of oral lichen planus is unknown. It is believed to result from an abnormal cell mediated immune response with infiltrating cell population composed of both T4 and T8 lymphocyte in the basal epithelial cells. They are recognized as foreign bodies because of changes in the antigenicity of their cells surface.⁸

The classic skin lesions of the cutaneous form of lichen planus can be described as purplish, polygonal, planar, pruritic papules and plaques. These skin lesions commonly involve the flexor surfaces of the legs and arms, especially the wrists.

The nail beds may also be affected, with resultant ridging, thinning and subungual hyperkeratosis. Scalp involvement, if untreated, can lead to scarring and permanent hair loss. Since 30% to 50% of patients with oral lesions also have cutaneous lesions, the presence of these characteristic cutaneous lesions can aid in the diagnosis of OLP.⁸

Although lichen planus can present with a variety of lesions, the most common presentation is as a well-defined area of purple-colored, itchy, flat-topped papules with interspersed lacy white lines (Wickham's striae). This description is known as the characteristic "6 Ps" of lichen planus: planar (flat-topped), purple, polygonal, pruritic, papules, and plaques. This rash, after regressing, is likely to leave an area of

hyperpigmentation that slowly fades.¹⁰ Reticular, the most common presentation of oral lichen planus, which is seen in present case as symptomatic and is characterized by the net-like or spider web like appearance of lacy white lines, oral variants of Wickham's striae. Erosive/ulcerative, the second most common type of oral lichen planus, is identified by oral ulcers presenting with persistent, irregular areas of redness, ulcerations and erosions covered with a unique yellow slough. This can occur in single or multiple areas of the mouth. In 25% of people with erosive oral lichen planus, the gingivae are involved, described commonly as desquamative gingivitis (a condition not unique to lichen planus). Following may be the initial or only signs of the condition.

- Papular, with white papules.
 - Plaque-like appearing as a white patch which may resemble leukoplakia.
 - Atrophic, appearing areas. Atrophic oral lichen planus may also manifest as desquamative gingivitis.
 - Bullous, appearing as fluid filled vesicles which project from the surface. The cause of OLP is unknown. It is said some certain factors mentioned below may trigger an inflammatory disorder.¹²⁻¹³⁻
- ¹⁴ Hepatitis C infection and other types of liver disease, Allergy-causing agents (allergens), such as foods,

dental materials or other substances, genetic background, Immunodeficiency disorder, Some bacterial and viral diseases, Certain medications for heart disease, High blood pressure or arthritis, Certain drugs like ibuprofen and naproxen, Stress, Graft versus host disease. Many controversies exist about the pathogenesis of OLP. A large body of evidence supports a role of immune dysregulation in the pathogenesis. The various mechanisms hypothesized to be involved in the immunopathogenesis are:¹⁵ Antigen-specific mechanism, Non-specific mechanisms, Autoimmune response, Humoral immunity. The diagnosis of OLP is based on a combination of characteristic clinical findings, history and histopathological examination. The hyperkeratotic (white) variant of OLP is often symptomless. The atrophic or the erythematous (red) variant and the erosive or the ulcerative (yellow) variants of OLP generally have persistent symptoms. Treatment of symptomatic OLP is challenging. Several drugs have been used with varying efficacy. Specific treatment includes corticosteroids (topical, intralesional or systemic), retinoids, cyclosporine, griseofulvin, hydroxychloroquine and dapsone.¹⁶ Non-pharmacological modalities include PUVA therapy, photodynamic therapy and LASER therapy. The most


commonly accepted treatment for lesions of OLP involves topical or systemic corticosteroids to change the patient's immune response. Topical corticosteroids are the commonly used in treating mild to moderately symptomatic lesions. Options (presented in terms of decreasing potency) include 0.05% clobetasol propionate gel, 0.1% or 0.05% betamethasone valerate gel, 0.05% fluocinonide gel, 0.05% clobetasol butyrate ointment or cream, and 0.1% triamcinolone acetonide ointment.¹⁷ The goal of treatment for symptomatic patients is palliation. The following flow-chart illustrates an easy protocol which will help in effective treatment. The most important issue concerning OLP is its potential for malignant transformation into OSCC. Although the WHO has categorized OLP as a potentially malignant epithelial lesion, the risk of malignant transformation of OLP remains a subject of debate in the literature. Some researchers accept the possible malignant potential of OLP, while others oppose this belief. Based on recent reports, the overall malignant transformation rate of OLP is estimated to be extremely low.¹⁹ A variety of systemic conditions may be associated with lesions of OLP and at times oral manifestations are the only signs and symptoms present in practice for the underlying condition as seen in our patient. And

since there is tendency for malignant transformation, it is elementary and fundamental as oral clinicians to make an accurate and timely diagnosis and render the appropriate treatment plan. As they rightly say “timely effort will prevent more work”

- **Pretreatment**



[Figure 1].



[Figure 2].



[Figure 3],

- **Post-treatment after 2 week.**



[Figure 4].

• **Post-treatment after 1 Month.**



[Figure 5].

References

1. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. *Clin Dermatol* 2010; 28(1):100–108.
2. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Oral lichen planus: clinical features and management. *J Oral Dis.* 2005; 1 (6): 338–349.
3. Boorghani M, Gholizadeh N, TaghaviZenouz A, Vatankhah M, Mehdipour M. Oral lichen planus: Clinical features, etiology, treatment and management; A review of literature. *J Dent Res Dent Clin Dent Prospects* 2010; 4:3-9.
4. Gujjar P, Zingade J, Patil S, Hallur J. Recent Update on Treatment Modalities of Oral Lichen Planus- A

- Review. *IJSS Case Reports & Reviews* 2015; 2(4):40-44.
5. Scully C (2008). *Oral and maxillofacial medicine: the Churchill Livingstone.* pp. 192–199.
6. Thongprasom, K; Carrozzo, M; Furness, S; Lodi, G. Interventions for treating oral lichen planus. *The Cochrane database of systematic reviews* (7): CD001168.
7. Oraguard-B – A pilot prospective study. *The Saudi Den J.* 2012; 24:143–148.
8. Rajendran R. Oral lichen planus. *J Oral Maxillofac Pathol.*2005; 9:3-5.
9. Katta R. Lichen planus. *Am Fam Physician* 2000; 61(11):3319-3328.
10. Usatine, RP; Tinitigan, M. Diagnosis and treatment of lichen planus. *Am Fam Physician* 84 (1): 53–60.
11. Alam F, Hamburger J. Oral mucosal lichen planus in children. *Int J Paediatr Dent.* 2001 May;11(3):209-14.
12. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and Lichenoid reactions; etiopathogenesis, diagnosis, management and malignant transformation. *J Oral Sci* 2007; 49:89–106.
13. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, Seymour GJ, Bigby M. The pathogenesis of oral lichen planus. *Crit Rev Oral Biol Med.* 2002; 13(4):350-365.

14. Sumairi B I, Kumar S K, Zain R B. Oral lichen planus and lichenoid reactions: etiopathogenesis diagnosis, management and malignant transformation. J Oral Sci,2007; 49(2):89- 106.

15. Singh P, Patel P, Raghu AR, Shergill A, Charlotte M. Current assessments regarding the pathogenesis and treatment strategies of oral lichen planus – a review. Asian Pac. J. Health Sci. 2014; 1(2): 96-103.

16. Laeijendecker R, Tank B, Dekker S, Neumann H. A Comparison of Treatment of Oral Lichen Planus with Topical Tacrolimus and Triamcinolone Acetonide Ointment- a clinical report. Acta Derm Venereol 2006; 86: 227–229.

17. Edwards P, Kelsch R. Oral Lichen Planus: Clinical Presentation and Management. J Can Dent Assoc 2002; 68(8):494-499.

18. Lavanya N, Jayanthi P, Rao U, Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment. J Oral Maxillofac Pathol. 2011 May-Aug; 15(2): 127–132.

19. Shirasuna K. Oral lichen planus: Malignant potential and diagnosis. Oral Sci. Int. 2014 Jan 1;11(1):1-7.

Corresponding Author Details:

Dr. Shubham Katakwar, PG student, Department of Oral Medicine and Radiology Saraswati Dhanwantari Dental College & Hospital & Post Graduate Research Institute, Parbhani, Maharashtra, India.